Latest Breaking News On - Diane abensur bessin - Page 1 : comparemela.com

Qualigen Therapeutics (QLGN) Acquires Majority Stake in NanoSynex

Qualigen Therapeutics (QLGN) Acquires Majority Stake in NanoSynex
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Shishir sinhaDiane abensur bessinMichelle heymannMichael poirierInstitute of medicineNanosynex coQualigen therapeutics incNanosynex ltdInteragency task force on antimicrobial resistanceAntimicrobial susceptibility testingMethicillin resistant staphylococcusInteragency task forceNanosynex co founderChief executive officerDiane abensurChief operating officer

2022-05-10 | NDAQ:QLGN | Press Release | Qualigen Therapeutics Inc

(2022-05-10 | NDAQ:QLGN) Qualigen Therapeutics' Partner NanoSynex to Present Technology at BioMed Israel

Tel avivQualigen closecurlyquoteDiane abensur bessinJules abrahamNanosynex closecurlyquoteShulamit levenbergMichael poirierIsrael innovation authority pavilionWorld health organizationNanosynex coDavid intercontinental hotel in tel avivDean of the technion institute technologyQualigen therapeutics incAboutqualigentherapeutics incExchange commissionPartners inc

Qualigen Acquires Majority Stake in Israel-based Diagnostics Developer NanoSynex

Qualigen expects to capitalize on synergies between its immunoassay diagnostics platform and NanoSynex's AST technology.

United statesDiane abensur bessinMichael poirierQualigen therapeuticsAbensur bessin

Qualigen Therapeutics (QLGN) to Acquire Majority Stake in Diagnostics Technology Company NanoSynex

Qualigen Therapeutics (QLGN) to Acquire Majority Stake in Diagnostics Technology Company NanoSynex
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Diane abensur bessinMichael poirierWorld health organizationQualigen therapeutics incNanosynex ltdOrphan drug designationAntimicrobial susceptibility testingChief executive officer

Israeli EMS Roll Outs COVID Rapid Tests With Biotech Startup Nanosynex

By NoCamels Team January 21, 2021 5 minutes Health & ScienceTech & Innovation United Hatzalah is rolling out rapid COVID testing kits in partnership with Israeli biotech startup Nanosynex. Courtesy Israeli emergency medical services organization United Hatzalah (UH) will be rolling out COVID-19 rapid diagnostic kits in partnership with Israeli biotech startup Nanosynex, as part of a pilot initiative to ramp up mass testing efforts affordably and efficiently. The kits consist of an antibody detection test (also known as a serological test), performed on blood extracted from a finger prick, and an antigen detection test, performed via a nasal swab. The antibody test determines the presence of COVID-19 antibodies; the antigen test detects fragments of proteins of SARS-CoV-2, the virus that causes COVID-19. Both tests have been proven effective, with sensitivity and specificity of well over 90 percent, and results are obtained in approximately 15 minutes.

South africaIsrael generalUnited kingdomDiane abensur bessinMichelle heymanMichelle heymannAbensur bessinEli beerShulamit levenbergWorld health organizationIsrael institute of technologyCourtesy technology news healthHealth ministryUnited hatzalahDov maiselTechnology news